Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BHC 
Bausch Health Companies Inc (BHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BHC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.08
1 Year Target Price $7.08
| 0 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.41% | Avg. Invested days 36 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.51B USD | Price to earnings Ratio 26.08 | 1Y Target Price 7.08 |
Price to earnings Ratio 26.08 | 1Y Target Price 7.08 | ||
Volume (30-day avg) 7 | Beta 0.48 | 52 Weeks Range 4.25 - 9.85 | Updated Date 09/16/2025 |
52 Weeks Range 4.25 - 9.85 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.99% | Operating Margin (TTM) 18.02% |
Management Effectiveness
Return on Assets (TTM) 4.35% | Return on Equity (TTM) -2304.54% |
Valuation
Trailing PE 26.08 | Forward PE 1.64 | Enterprise Value 22498351271 | Price to Sales(TTM) 0.25 |
Enterprise Value 22498351271 | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 2.28 | Enterprise Value to EBITDA 7.5 | Shares Outstanding 369790016 | Shares Floating 225627563 |
Shares Outstanding 369790016 | Shares Floating 225627563 | ||
Percent Insiders 10.78 | Percent Institutions 68.49 |
Upturn AI SWOT
Bausch Health Companies Inc
Company Overview
History and Background
Bausch Health Companies Inc. was founded in 1853 as Bausch & Lomb. It evolved from a small optical goods shop to a global pharmaceutical and medical device company. Significant milestones include expanding into vision care, pharmaceuticals, and surgical devices, and the acquisition by Valeant Pharmaceuticals in 2013. Valeant rebranded as Bausch Health in 2018 to rebuild its reputation.
Core Business Areas
- Bausch + Lomb: Focuses on vision care products, including contact lenses, lens care products, and ophthalmic pharmaceuticals.
- Salix Pharmaceuticals: Develops and markets gastrointestinal (GI) products, addressing conditions like irritable bowel syndrome and hepatic encephalopathy.
- International Rx: Markets a range of branded and generic pharmaceutical products outside the United States.
Leadership and Structure
The CEO of Bausch Health is Thomas Appio. The organizational structure includes various business units focused on specific product lines and geographic regions. The company has a board of directors that oversees the company's management and strategy.
Top Products and Market Share
Key Offerings
- XIFAXAN: A gastrointestinal-specific antibiotic used to treat irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy. Competitors include other IBS-D and HE treatments. Xifaxan generated significant revenue for Salix Pharmaceuticals, a Bausch Health subsidiary. Market share is substantial in its treatment areas, though precise figures fluctuate. Competitors include Allergan (now AbbVie) and Novartis.
- Lotemax: A corticosteroid ophthalmic suspension and gel used to treat inflammation of the eye. Key competitors include generic versions of similar steroids and branded products from companies like Novartis and Allergan (now AbbVie). Lotemax holds a notable market share within its segment of ophthalmic corticosteroids. It is one of the market leading medications for this treatment.
- Bausch + Lomb ULTRA: A family of monthly replacement contact lenses. Key competitors include Alcon (Novartis), Johnson & Johnson Vision, and CooperVision. This product maintains a significant share of the contact lens market, competing on comfort and breathability.
Market Dynamics
Industry Overview
The pharmaceutical and medical device industries are characterized by intense competition, regulatory scrutiny, and the need for constant innovation. Growth is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements.
Positioning
Bausch Health is positioned as a diversified pharmaceutical and medical device company with a focus on branded products and strategic acquisitions. Its competitive advantages include a strong portfolio of established products and a global distribution network.
Total Addressable Market (TAM)
The TAM for Bausch Health's combined segments (vision care, GI, and international pharmaceuticals) is estimated to be in the hundreds of billions of dollars. Bausch Health's positioning allows it to address specific segments within this TAM with targeted products and marketing strategies.
Upturn SWOT Analysis
Strengths
- Established brand portfolio
- Global distribution network
- Strong position in key therapeutic areas
- Experienced management team
- Focus on innovation and product development
Weaknesses
- High debt levels (though significantly reduced)
- History of accounting irregularities (legacy issues)
- Dependence on key products
- Exposure to generic competition
- Complex organizational structure
Opportunities
- Strategic acquisitions
- Geographic expansion
- New product launches
- Partnerships and collaborations
- Growth in emerging markets
Threats
- Generic competition
- Regulatory changes
- Pricing pressures
- Product liability litigation
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- NVS
- ALC
- COOP
Competitive Landscape
Bausch Health faces intense competition from larger pharmaceutical and medical device companies. Its advantages include a focused portfolio and established brands, while its disadvantages include high debt and legacy issues.
Major Acquisitions
Qunar
- Year: 2016
- Acquisition Price (USD millions): 0
- Strategic Rationale: Acquired as part of the Valeant merger which has brought up its medical device offerings. This helped bring in significant revenue to the company
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been impacted by debt issues and restructuring. Recent years are showing signs of stabilization and growth.
Future Projections: Future growth projections depend on successful product launches, debt reduction, and strategic acquisitions. Analyst estimates vary.
Recent Initiatives: Recent initiatives include focusing on core businesses, divesting non-core assets, reducing debt, and investing in R&D.
Summary
Bausch Health is a company in recovery, having successfully navigated a period of significant financial distress. The company's focus on core businesses like Bausch + Lomb and Salix shows promise, but high debt levels remain a concern. Successful product launches and strategic acquisitions will be critical for future growth. The company must remain focused on debt reduction and brand reputation improvement.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Bausch Health Investor Relations
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market data and competitor information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch Health Companies Inc
Exchange NYSE | Headquaters Laval, QC, Canada | ||
IPO Launch date 1994-03-29 | CEO & Director Mr. Thomas J. Appio | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 20700 | Website https://www.bauschhealth.com |
Full time employees 20700 | Website https://www.bauschhealth.com | ||
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.